AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:FOMXFoamix Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.99
0.00 (0.00 %)
(As of 03/9/2020)
Add
Compare
Today's Range
$2.99
Now: $2.99
$2.99
50-Day Range
$2.99
MA: $2.99
$2.99
52-Week Range
$1.97
Now: $2.99
$4.84
VolumeN/A
Average Volume518,350 shs
Market Capitalization$184.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Read More
Foamix Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.60 million
Book Value$1.70 per share

Profitability

Net Income$-74,160,000.00

Miscellaneous

Employees80
Market Cap$184.12 million
Next Earnings DateN/A
OptionableOptionable

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Foamix Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Foamix Pharmaceuticals.

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07. View Foamix Pharmaceuticals' earnings history.

What price target have analysts set for FOMX?

3 analysts have issued 1 year price objectives for Foamix Pharmaceuticals' shares. Their forecasts range from $11.00 to $30.00. On average, they anticipate Foamix Pharmaceuticals' share price to reach $17.33 in the next year. This suggests a possible upside of 479.7% from the stock's current price. View analysts' price targets for Foamix Pharmaceuticals.

Has Foamix Pharmaceuticals been receiving favorable news coverage?

News articles about FOMX stock have trended negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Foamix Pharmaceuticals.

Who are some of Foamix Pharmaceuticals' key competitors?

What other stocks do shareholders of Foamix Pharmaceuticals own?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the following people:
  • Mr. David T. Domzalski, CEO & Director (Age 52)
  • Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)
  • Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)
  • Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
  • Dr. Iain A. Stuart, Chief R&D Officer (Age 46)

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $2.99.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $184.12 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe.

What is Foamix Pharmaceuticals' official website?

The official website for Foamix Pharmaceuticals is www.foamix.com.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.